

Hugh S Griffith Chief Executive Officer T: +44 (0) 131 248 3660 E: info@nucanabiomed.com W: www.nucanabiomed.com

Edinburgh, U.K., 5 September 2013

NuCana to attend ESMO 2013 in Amsterdam on 27th September 2013.

NuCana (www.nucanabiomed.com) today announced it will be sending a senior scientific team to the European Cancer Congress in Amsterdam, September 2013 and will conduct Advisory Board meetings with key opinion leaders from around Europe. The aim is to discuss the optimal registration studies for our portfolio of novel anti-cancer agents, ProTides.

"Our lead ProTide, Acelarin™ (NUC-1031) is advancing rapidly through early clinical studies and is generating strong signals of efficacy coupled with minimal toxicity" commented Hugh Griffith, CEO of NuCana. He added "the registration studies are being planned and we are seeking ways to fast track the approval of these important new medicines".

Nucana has three other ProTides in advanced stage of non clinical development with plans to bring them to the clinic within the next 12-18 months. The ESMO conference is a valuable forum at which to discuss the role of these new agents in cancer treatment.

This year the European Cancer Congress (ECC) is co-organised by the European Society for Medical Oncology (ESMO) in partnership with ECCO and ESTRO. The ECC 2013 fosters the current best practices for future progress in cancer therapy, research and care.

About NuCana

NuCana is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

For further information, please visit www.nucana.com

About ProTides

The distinctive feature of a ProTide is the ability to bypass the key cancer cell resistance pathways and generate high levels of the active agent inside the cancer cells. The fundamental aspect of the ProTide technology platform is the addition of a phosphoramidate moiety onto a nucleoside analogue scaffold. As such, it is applicable to all nucleoside analogues. NuCana's vision is to replace all commonly used nucleoside analogue-based treatments with more active and safer ProTides.